Loading...
•
Mar 31
Cencora Q2 2025 Earnings Report
Cencora reported strong growth in revenue and earnings in Q2 2025, driven by its U.S. Healthcare Solutions segment and strategic acquisition of Retina Consultants of America.
Key Takeaways
Cencora delivered robust Q2 results with $75.5B in revenue and a significant boost in earnings. The company raised its full-year adjusted EPS guidance due to continued strength in the U.S. Healthcare Solutions segment.
Revenue reached $75.5 billion, up 10.3% year-over-year.
GAAP EPS increased to $3.68; Adjusted EPS was $4.42.
Net income rose to $717,871,000 driven by strong gross profit and operating leverage.
Guidance for FY25 adjusted EPS raised to $15.70–$15.95.
Cencora
Cencora
Cencora Revenue by Segment
Cencora Revenue by Geographic Location
Revenue by Segment
U.S. Healthcare Revenue
CapyFin.comIntl. Healthcare Revenue
CapyFin.comRevenue by Geographic Location
United States Revenue
CapyFin.comInternational Revenue
CapyFin.com Forward Guidance
Cencora increased its full-year 2025 adjusted EPS guidance, supported by strong U.S. segment growth and operational efficiency, though international operations remain a drag.
Positive Outlook
- Raised FY25 adjusted EPS guidance to $15.70–$15.95.
- U.S. Healthcare Solutions operating income expected to grow 17.5–19.5%.
- Adjusted consolidated operating income expected to grow 13.5–15.5%.
- Constant currency revenue growth of 6–8% expected for International segment.
- Weighted average diluted shares revised down to 195.0–195.5M.
Challenges Ahead
- International segment reported operating income expected to decline 1–4%.
- On a constant currency basis, International operating income expected to be flat to down 3%.
- Revenues from International segment revised down to 3–4% growth.
- Higher interest expenses due to recent debt financing.
- Macroeconomic challenges continue to affect international logistics and currency.
Revenue & Expenses
Visualization of income flow from segment revenue to net income